Last reviewed · How we verify
VYEPTI (EPTINEZUMAB-JJMR)
VYEPTI (generic name: EPTINEZUMAB-JJMR) is a Calcitonin Gene-related Peptide Antagonist [EPC] drug developed by Lundbeck Seattle BioPharmaceuticals, Inc.. It is currently FDA-approved for Migraine, Prevention of migraine attacks.
At a glance
| Generic name | EPTINEZUMAB-JJMR |
|---|---|
| Sponsor | Lundbeck Seattle BioPharmaceuticals, Inc. |
| Drug class | Calcitonin Gene-related Peptide Antagonist [EPC] |
| Target | Calcitonin gene-related peptide 1, Calcitonin gene-related peptide 2 |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Migraine
- Prevention of migraine attacks
Common side effects
- Nasopharyngitis
- Hypersensitivity reactions
Serious adverse events
- Anaphylaxis
- Hypertension
- Raynaud's phenomenon
- Fatigue
Key clinical trials
- Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of IV Eptinezumab in Adolescents (12-17 Years) for the Preventive Treatment of Ch (Phase 3)
- Migraine Medication Effects on Urinary Symptoms (N/A)
- Long-term, Open-label (Dose-blinded), Extension Study of Eptinezumab in Children and Adolescents With Chronic or Episodic Migraine (Phase 3)
- A Parallel Group, Double-Blind, Randomized, Placebo Controlled, Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Frequent Episodic Migraines (Phase 3)
- Interventional, Open-label, Fixed-dose Multiple Administration Study to Evaluate Long-term Treatment With Eptinezumab in Patients With Chronic Cluster Headache (Phase 3)
- A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine (Phase 3)
- A Parallel Group, Double-Blind, Randomized, Placebo Controlled, Dose-Ranging Phase 2 Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of ALD403 Administered Intravenously in Patients With (Phase 2)
- An Open Label Phase 3 Trial to Evaluate the Safety of ALD403 Administered Intravenously in Patients With Chronic Migraines (Phase 3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VYEPTI CI brief — competitive landscape report
- VYEPTI updates RSS · CI watch RSS
- Lundbeck Seattle BioPharmaceuticals, Inc. portfolio CI
Frequently asked questions about VYEPTI
What is VYEPTI?
VYEPTI (EPTINEZUMAB-JJMR) is a Calcitonin Gene-related Peptide Antagonist [EPC] drug developed by Lundbeck Seattle BioPharmaceuticals, Inc., indicated for Migraine, Prevention of migraine attacks.
What is VYEPTI used for?
VYEPTI is indicated for Migraine, Prevention of migraine attacks.
Who makes VYEPTI?
VYEPTI is developed and marketed by Lundbeck Seattle BioPharmaceuticals, Inc. (see full Lundbeck Seattle BioPharmaceuticals, Inc. pipeline at /company/lundbeck-seattle-biopharmaceuticals-inc).
What is the generic name of VYEPTI?
EPTINEZUMAB-JJMR is the generic (nonproprietary) name of VYEPTI.
What drug class is VYEPTI in?
VYEPTI belongs to the Calcitonin Gene-related Peptide Antagonist [EPC] class. See all Calcitonin Gene-related Peptide Antagonist [EPC] drugs at /class/calcitonin-gene-related-peptide-antagonist-epc.
What development phase is VYEPTI in?
VYEPTI is FDA-approved (marketed).
What are the side effects of VYEPTI?
Common side effects of VYEPTI include Nasopharyngitis, Hypersensitivity reactions. Serious adverse events: Anaphylaxis, Hypertension, Raynaud's phenomenon, Fatigue.
What does VYEPTI target?
VYEPTI targets Calcitonin gene-related peptide 1, Calcitonin gene-related peptide 2 and is a Calcitonin Gene-related Peptide Antagonist [EPC].
Related
- Drug class: All Calcitonin Gene-related Peptide Antagonist [EPC] drugs
- Target: All drugs targeting Calcitonin gene-related peptide 1, Calcitonin gene-related peptide 2
- Manufacturer: Lundbeck Seattle BioPharmaceuticals, Inc. — full pipeline
- Therapeutic area: All drugs in Neuroscience
- Indication: Drugs for Migraine
- Indication: Drugs for Prevention of migraine attacks
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing